ArticleSaudi medical journal2023
Prevalence of extended-spectrum β-lactamase and carbapenem-resistant
Article in Saudi medical journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 5 citations in OpenAlex.
- Carbapenem-ResistantMicroorganisms · 2026Review
- Determinants of Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2026Article
- From burden to action: Saudi Arabia's strategy on antimicrobial resistance.Open medicine (Warsaw, Poland) · 2026Review
- Phenotypic and molecular characterization of Klebsiella pneumoniae in neonates and pediatric patients: antibiotic resistance, β-Lactamase genes, and sociodemographic risk factors.BMC infectious diseases · 2025Article
- A Decade-Long Review of the Virulence, Resistance, and Epidemiological Risks ofMicroorganisms · 2024Review
- Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2024Review
- Predominance of OXA-48 carbapenemase-producingBiomolecules & biomedicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo assess the prevalence of these resistant strains in the overall isolates of
methodsThis retrospective study was conducted from November 2020 to November 2021. The identification and antibiotic susceptibility testing were performed using standard laboratory methods according to the EUCAST standards. The detection of ESBL and carbapenemase production was performed using phenotypic methods such as E-test, combined-disk test with various inhibitors (ROSCO Diagnostica A/S), chromogenic medium for the detection of ESBL/carbapenemase-producing Enterobacteriaceae (CPE) isolates, and the VITEK 2 Compact system (BioMerieux).
results944 isolates of
conclusionOur results show an increasing frequency of CRKP strains. This presents a significant issue in terms of infection prevention and control in hospital settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.